Table 1 Characteristics of randomised controlled trials assessing treatment of vaginal candidiasis to prevent preterm birth
Study | Study period and location | Study population | Study size (Candidiasis) | Intervention | Comparison | Available outcomes among women with candidiasis | Funding and competing interests |
|---|---|---|---|---|---|---|---|
Kiss et al. | 2001 to 2002, 25 non-hospital-based obstetricians Vienna, Austria | Women with singleton pregnancies, 150 to 196 weeks gestation, no symptoms of vaginal infection, bleeding or contractions, Mean age [SD]: 28.9 [±5.6], 48% primipara 98% white ethnicity, Carriage rate of asymptomatic candidiasis: 14.1% | 586, 294 randomised to treatment 292 randomised to usual care | Vaginal clotrimazole 0.1 g for 6 days | Usual care (vaginal culture result not revealed, no treatment) | Spontaneous preterm birth (<37 weeks gestation) | ‘Healthy Austria’ (‘Fonds GesundesÖsterreich’) grant PNr.205/V/12 and Federal Ministry of Education, Science, and Culture grant, GZ 70.069/1-Pr4/2000, no competing interests declared. |
Roberts et al. | 2008 to 2009, single tertiary obstetric hospital, Sydney, Australia | Women with singleton pregnancies, 120 to 196 weeks gestation, no symptoms vaginal infection, mean age [SD]: 32.2 [±54.4], 45% primipara, ethnicity not reported, carriage rate of asymptomatic candidiasis: 19.6% | 99, 50 randomised to treatment, 49 randomised to usual care | Vaginal clotrimazole 0.1 g for 6 days | Usual care (vaginal culture result not revealed, no treatment) | Spontaneous preterm birth (<37 weeks gestation); any preterm birth; pregnancy complications (gestational diabetes; antepartum haemorrhage); mode of delivery (spontaneous vaginal, instrumental caesarean section), birth weight (<2,500, 2,500 to 3,999, ≥4,000 g); nursery admission. | One author supported by an Australian National Health and Medical Research Council Fellowship. No competing interests declared.* |